Beta-Adrenoceptor Antagonists and the Physiological Response to Exercise: Clinical Implications for Training and Rehabilitation
DOI:
https://doi.org/10.12775/QS.2026.53.69721Keywords
beta-blockers, beta-adrenoceptor antagonists, exercise capacity, ventilatory threshold, cardiopulmonary exercise testingAbstract
Aim: This narrative review aimed to analyze the impact of beta-adrenoceptor antagonists on the physiological response to exercise and to identify clinical implications for exercise training prescription and exercise-based rehabilitation in patients receiving long-term pharmacotherapy.
Material and Methods: A structured literature search was conducted in PubMed, Embase, and the Cochrane Library for studies published between January 2018 and February 2026. Randomized controlled trials, crossover studies, observational research, and relevant systematic reviews evaluating the effects of cardioselective and non-selective beta-adrenoceptor antagonists on peak oxygen uptake (VO₂peak), heart rate response, and ventilatory thresholds in healthy and clinical populations were included. Due to heterogeneity in study design, populations, and pharmacological regimens, findings were synthesized narratively without quantitative meta-analysis.
Results: Beta-adrenoceptor antagonists consistently attenuate the chronotropic response to exercise, typically reducing maximal heart rate by approximately 18–19%. Despite this effect, VO₂peak and maximal power output are often preserved through compensatory mechanisms such as increased stroke volume and enhanced arteriovenous oxygen extraction. Under beta-blockade, the relationship between heart rate and external workload becomes blunted, limiting the reliability of heart rate–based methods (e.g., %HRmax, HRR) for exercise intensity prescription.
Conclusions: Exercise-based rehabilitation in patients treated with beta-adrenoceptor antagonists requires an individualized, physiology-guided approach. Cardiopulmonary exercise testing with determination of ventilatory thresholds (VT1 and VT2) should be preferred for exercise prescription. In settings without access to CPET, subjective measures such as the Borg Rating of Perceived Exertion scale and the talk test should be incorporated to ensure safety and training effectiveness.
References
1. Andersen JT, Ergen E, Hazir T, et al. Effects of beta-blockers on archery performance, body sway and aiming behaviour: a randomised, double-blind, placebo-controlled, cross-over trial. BMJ Open Sport Exerc Med. 2021;7(2):e001071. doi:10.1136/bmjsem-2021-001071
2. Mendes RG, Castro R, Araujo CJ, Maia FL. Beta-blockers and exercise tolerance. Rev Bras Anestesiol. 2004;54(2):232–241.
3. Vanhees L, Fagard R, Thijs L, Amery A. Influence of beta-blockade on exercise capacity. Prog Cardiovasc Dis. 2004;46(5):365–372. doi:10.1016/j.pcad.2003.11.003
4. Priel E, Friedmann O, Smolev M, Sharabi Y, Weinstock-Guttman B. Acute beta1-blockade does not reduce maximal oxygen uptake in healthy adults. Front Physiol. 2021;12:656345. doi:10.3389/fphys.2021.656345
5. Montero D, Flammer AJ. Effect of beta-blockers on V̇O₂peak in heart failure: systematic review and meta-analysis. Sports Med. 2018;48(8):1605–1617. doi:10.1007/s40279-018-0969-2
6. Birnbaumer P, Auersperger I, Hotter B, et al. Pattern of the heart rate performance curve in beta-blocked subjects and healthy controls. Sports. 2018;6(3):61. doi:10.3390/sports6030061
7. Pelliccia A, Sharma S, Gati S, et al. Exercise intensity assessment and prescription in cardiovascular disease: a clinical update. Eur J Prev Cardiol. 2021;28(12):1303-1318. doi:10.1093/eurjpc/zwab007
8. Wonisch M, Hofmann P, Fruhwald F, et al. Influence of beta-blocker use on percentage of target heart rate exercise prescription. Eur J Cardiovasc Prev Rehabil. 2003;10(4):296–301. doi:10.1097/01.hjr.0000085246.96747.11
9. Mitchell BL, Davison K, Parfitt G, et al. Physiological and perceived exertion responses during exercise: effect of β-blockade. Med Sci Sports Exerc. 2019;51(4):782–791. doi:10.1249/MSS.0000000000001845
10. Mezzani A, Hamm LF, Jones AYM, et al. Cardiopulmonary exercise testing in cardiac rehabilitation: a scientific statement from the American Heart Association. Circulation. 2022;145(17):e1019–e1037. doi:10.1161/CIR.0000000000001075
11. Xie J, Qi F, Zhang H, et al. Beta-blocker effects on exercise capacity and ventilatory threshold. PLoS One. 2022;17(12):e0279171. doi:10.1371/journal.pone.0279171
12. Bangalore S, Messerli FH, Wun CC, et al. β-blocker use and cardiovascular outcomes in contemporary practice: a meta-analysis. Am J Med. 2007;120(2):149-154. doi:10.1016/j.amjmed.2006.08.014
13. Williams B, Mancia G, Spiering W, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi:10.1097/HJH.0000000000003480
14. Whelton PK, Carey RM, Aronow WS, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. doi:10.1093/eurheartj/ehae178
15. Dahlöf B. β-blockade for patients with hypertension, ischemic heart disease or heart failure – where are we now? Vasc Health Risk Manag. 2021;17:337–348. doi:10.2147/VHRM.S285907
16. Schmied C, Ostermann M, Hofmann P, et al. Effects of beta-blockade on exercise physiology. Sci Rep. 2020;10(1):79837. doi:10.1038/s41598-020-79837-3
17. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Beta-blockers in hypertension and cardiovascular disease: a critical reappraisal. Curr Med Res Opin. 2024;40(2):151–164. doi:10.1080/03007995.2024.2318058
18. Bavishi C, Bangalore S, Shamsuzzaman M, et al. Beta-blockers and exercise response: clinical implications. Curr Med Res Opin. 2024;40(1):87–96. doi:10.1080/03007995.2024.2317433
19. Patel HC, Hayward C, Ozkor M, et al. Exercise prescription under beta-blockade. Sports Med. 2013;43(11):1121–1134. doi:10.1007/s40279-013-0095-7
20. Al-Khatib SM, Antman EM, Lamas GA, et al. Adrenergic receptor pharmacology in cardiovascular disease. Curr Cardiol Rev. 2021;17(3):180–190. doi:10.2174/1573403X176662101191009
21. Cojocariu SA, Maștaleru A, Sascău RA, et al. Neuropsychiatric consequences of lipophilic beta-blockers. Medicina (Kaunas). 2021;57(2):155. doi:10.3390/medicina57020155
22. Michel MC, Michel-Reher MB, Hein P. A systematic review of inverse agonism at adrenoceptor subtypes. Cells. 2020;9(9):1923. doi:10.3390/cells9091923.
23. Hundemer GL, Canney M. β-blockers in hemodialysis: simple questions, complicated answers. Clin Kidney J. 2021;14(3):731–734. doi:10.1093/ckj/sfaa249.
24. AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic properties of highly selective β-blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease. Cardiovasc Drugs Ther. 2022;36:959–971. doi:10.1007/s10557-021-07205-y.
25. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368.
26. Assimon MM, Flythe JE. A comparative study of carvedilol versus metoprolol initiation and mortality risk among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2018;72(3):337–348. doi:10.1053/j.ajkd.2018.02.358
27. Hundemer GL, Curhan GC. Beta-blocker use and outcomes in patients with chronic kidney disease. Clin Kidney J. 2021;14(3):983–991. doi:10.1093/ckj/sfaa289
28. Frishman WH. Beta-adrenergic blockade in cardiovascular disease. J Clin Hypertens. 2016;18(11):1032–1041. doi:10.1111/jch.12864
29. Carerj S, Zito C, Di Bella G, et al. Left ventricular deformation analysis by speckle tracking echocardiography in cardiovascular disease. Int J Cardiovasc Imaging. 2019;35(7):1231–1240. doi:10.1007/s10554-019-01560-6
30. Bryniczka I, Jezierski M, Nowicka E, Patrzykąt KM, Gorzoch-Burduk Z, Puzio J, Marcinkowska P, Krzyżaniak M, Popielarska K, Wróblewska K. Old drugs, new roles: non-cardiac uses of beta-blockers – an updated systematic review. Quality in Sport. 2025;48:66932. doi:10.12775/QS.2025.48.66932.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Agnieszka Olejnik, Mateusz Zdaniewicz, Jakub Adamiak, Michał Maciejowski, Bartłomiej Czyżak, Adrian Baran, Justyna Jankowska, Konrad Gronek, Beata Huszcza, Edward Zheng

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 246
Number of citations: 0